Browsing Tag
fanregratinib
2 posts
HUTCHMED gets priority review for fanregratinib in FGFR2-positive cholangiocarcinoma in China
HUTCHMED’s fanregratinib gains NDA acceptance with priority review in China. Find out what it means for FGFR2-driven cancers and precision oncology adoption.
HUTCHMED’s ATTC platform and fruquintinib combo data headline 2025 R&D updates
Find out how HUTCHMED’s new ATTC platform and strong late-stage trial results could reshape its cancer drug pipeline and investor outlook today.